Cargando…
MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
OBJECTIVE: To optimize sensitivity and disease specificity of a myelin oligodendrocyte glycoprotein (MOG) antibody assay. METHODS: Consecutive sera (n = 1,109) sent for aquaporin-4 (AQP4) antibody testing were screened for MOG antibodies (Abs) by cell-based assays using either full-length human MOG...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370386/ https://www.ncbi.nlm.nih.gov/pubmed/25821844 http://dx.doi.org/10.1212/NXI.0000000000000089 |
_version_ | 1782362863151611904 |
---|---|
author | Waters, Patrick Woodhall, Mark O'Connor, Kevin C. Reindl, Markus Lang, Bethan Sato, Douglas K. Juryńczyk, Maciej Tackley, George Rocha, Joao Takahashi, Toshiyuki Misu, Tatsuro Nakashima, Ichiro Palace, Jacqueline Fujihara, Kazuo Leite, M. Isabel Vincent, Angela |
author_facet | Waters, Patrick Woodhall, Mark O'Connor, Kevin C. Reindl, Markus Lang, Bethan Sato, Douglas K. Juryńczyk, Maciej Tackley, George Rocha, Joao Takahashi, Toshiyuki Misu, Tatsuro Nakashima, Ichiro Palace, Jacqueline Fujihara, Kazuo Leite, M. Isabel Vincent, Angela |
author_sort | Waters, Patrick |
collection | PubMed |
description | OBJECTIVE: To optimize sensitivity and disease specificity of a myelin oligodendrocyte glycoprotein (MOG) antibody assay. METHODS: Consecutive sera (n = 1,109) sent for aquaporin-4 (AQP4) antibody testing were screened for MOG antibodies (Abs) by cell-based assays using either full-length human MOG (FL-MOG) or the short-length form (SL-MOG). The Abs were initially detected by Alexa Fluor goat anti-human IgG (H + L) and subsequently by Alexa Fluor mouse antibodies to human IgG1. RESULTS: When tested at 1:20 dilution, 40/1,109 sera were positive for AQP4-Abs, 21 for SL-MOG, and 180 for FL-MOG. Only one of the 40 AQP4-Ab–positive sera was positive for SL-MOG-Abs, but 10 (25%) were positive for FL-MOG-Abs (p = 0.0069). Of equal concern, 48% (42/88) of sera from controls (patients with epilepsy) were positive by FL-MOG assay. However, using an IgG1-specific secondary antibody, only 65/1,109 (5.8%) sera were positive on FL-MOG, and AQP4-Ab– positive and control sera were negative. IgM reactivity accounted for the remaining anti-human IgG (H + L) positivity toward FL-MOG. The clinical diagnoses were obtained in 33 FL-MOG–positive patients, blinded to the antibody data. IgG1-Abs to FL-MOG were associated with optic neuritis (n = 11), AQP4-seronegative neuromyelitis optica spectrum disorder (n = 4), and acute disseminated encephalomyelitis (n = 1). All 7 patients with probable multiple sclerosis (MS) were MOG-IgG1 negative. CONCLUSIONS: The limited disease specificity of FL-MOG-Abs identified using Alexa Fluor goat anti-human IgG (H + L) is due in part to detection of IgM-Abs. Use of the FL-MOG and restricting to IgG1-Abs substantially improves specificity for non-MS demyelinating diseases. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the presence of serum IgG1- MOG-Abs in AQP4-Ab–negative patients distinguishes non-MS CNS demyelinating disorders from MS (sensitivity 24%, 95% confidence interval [CI] 9%–45%; specificity 100%, 95% CI 88%–100%). |
format | Online Article Text |
id | pubmed-4370386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-43703862015-03-27 MOG cell-based assay detects non-MS patients with inflammatory neurologic disease Waters, Patrick Woodhall, Mark O'Connor, Kevin C. Reindl, Markus Lang, Bethan Sato, Douglas K. Juryńczyk, Maciej Tackley, George Rocha, Joao Takahashi, Toshiyuki Misu, Tatsuro Nakashima, Ichiro Palace, Jacqueline Fujihara, Kazuo Leite, M. Isabel Vincent, Angela Neurol Neuroimmunol Neuroinflamm Article OBJECTIVE: To optimize sensitivity and disease specificity of a myelin oligodendrocyte glycoprotein (MOG) antibody assay. METHODS: Consecutive sera (n = 1,109) sent for aquaporin-4 (AQP4) antibody testing were screened for MOG antibodies (Abs) by cell-based assays using either full-length human MOG (FL-MOG) or the short-length form (SL-MOG). The Abs were initially detected by Alexa Fluor goat anti-human IgG (H + L) and subsequently by Alexa Fluor mouse antibodies to human IgG1. RESULTS: When tested at 1:20 dilution, 40/1,109 sera were positive for AQP4-Abs, 21 for SL-MOG, and 180 for FL-MOG. Only one of the 40 AQP4-Ab–positive sera was positive for SL-MOG-Abs, but 10 (25%) were positive for FL-MOG-Abs (p = 0.0069). Of equal concern, 48% (42/88) of sera from controls (patients with epilepsy) were positive by FL-MOG assay. However, using an IgG1-specific secondary antibody, only 65/1,109 (5.8%) sera were positive on FL-MOG, and AQP4-Ab– positive and control sera were negative. IgM reactivity accounted for the remaining anti-human IgG (H + L) positivity toward FL-MOG. The clinical diagnoses were obtained in 33 FL-MOG–positive patients, blinded to the antibody data. IgG1-Abs to FL-MOG were associated with optic neuritis (n = 11), AQP4-seronegative neuromyelitis optica spectrum disorder (n = 4), and acute disseminated encephalomyelitis (n = 1). All 7 patients with probable multiple sclerosis (MS) were MOG-IgG1 negative. CONCLUSIONS: The limited disease specificity of FL-MOG-Abs identified using Alexa Fluor goat anti-human IgG (H + L) is due in part to detection of IgM-Abs. Use of the FL-MOG and restricting to IgG1-Abs substantially improves specificity for non-MS demyelinating diseases. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the presence of serum IgG1- MOG-Abs in AQP4-Ab–negative patients distinguishes non-MS CNS demyelinating disorders from MS (sensitivity 24%, 95% confidence interval [CI] 9%–45%; specificity 100%, 95% CI 88%–100%). Lippincott Williams & Wilkins 2015-03-19 /pmc/articles/PMC4370386/ /pubmed/25821844 http://dx.doi.org/10.1212/NXI.0000000000000089 Text en © 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Article Waters, Patrick Woodhall, Mark O'Connor, Kevin C. Reindl, Markus Lang, Bethan Sato, Douglas K. Juryńczyk, Maciej Tackley, George Rocha, Joao Takahashi, Toshiyuki Misu, Tatsuro Nakashima, Ichiro Palace, Jacqueline Fujihara, Kazuo Leite, M. Isabel Vincent, Angela MOG cell-based assay detects non-MS patients with inflammatory neurologic disease |
title | MOG cell-based assay detects non-MS patients with inflammatory neurologic disease |
title_full | MOG cell-based assay detects non-MS patients with inflammatory neurologic disease |
title_fullStr | MOG cell-based assay detects non-MS patients with inflammatory neurologic disease |
title_full_unstemmed | MOG cell-based assay detects non-MS patients with inflammatory neurologic disease |
title_short | MOG cell-based assay detects non-MS patients with inflammatory neurologic disease |
title_sort | mog cell-based assay detects non-ms patients with inflammatory neurologic disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370386/ https://www.ncbi.nlm.nih.gov/pubmed/25821844 http://dx.doi.org/10.1212/NXI.0000000000000089 |
work_keys_str_mv | AT waterspatrick mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT woodhallmark mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT oconnorkevinc mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT reindlmarkus mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT langbethan mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT satodouglask mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT jurynczykmaciej mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT tackleygeorge mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT rochajoao mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT takahashitoshiyuki mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT misutatsuro mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT nakashimaichiro mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT palacejacqueline mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT fujiharakazuo mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT leitemisabel mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease AT vincentangela mogcellbasedassaydetectsnonmspatientswithinflammatoryneurologicdisease |